arrow_back Back to App

Independent Drug Value Assessment: More Transparency in Prices and Benefits

This act mandates independent value assessments for new and certain existing drugs. The goal is to provide citizens with clear information on the economic and health benefits of medications, potentially influencing their prices and accessibility. This will help citizens better understand what they are paying for and the real benefits of treatment.
Key points
New drugs and those with new uses will undergo mandatory independent value assessment within 90 days of approval.
Within 5 years, at least 25 existing drugs will be assessed, prioritizing high-expenditure and breakthrough therapies.
Assessments will be publicly available on the Department of Health and Human Services website, excluding confidential information.
Assessments will consider benefits to patients (quality and duration of life), families, employers, and healthcare system savings.
The act prohibits the use of Quality-Adjusted Life Year (QALY) and discrimination in valuing life based on age, illness, or disability.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_9321
Sponsor: Rep. Speier, Jackie [D-CA-14]
Process start date: 2022-11-16
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Independent Drug Value Assessment Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_9321.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-11-16.

What are the main provisions?

Key points include:

  • New drugs and those with new uses will undergo mandatory independent value assessment within 90 days of approval.
  • Within 5 years, at least 25 existing drugs will be assessed, prioritizing high-expenditure and breakthrough therapies.
  • Assessments will be publicly available on the Department of Health and Human Services website, excluding confidential information.
  • Assessments will consider benefits to patients (quality and duration of life), families, employers, and healthcare system savings.
  • The act prohibits the use of Quality-Adjusted Life Year (QALY) and discrimination in valuing life based on age, illness, or disability.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Speier, Jackie [D-CA-14].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health